Tempus (@TempusAI) / X

Tempus

1,415 posts

Tempus

@TempusAI

Tempus is a technology company leading the adoption of #AI to advance precision medicine.

Chicago, IL

Joined October 2015

Tempus
@TempusAI
May 29, 2025
Yesterday we were the target of a small short seller that apparently makes its living publishing inaccurate content designed to mislead investors. We do not intend to respond through the media to a report that is riddled with inaccuracies, conjecture, and ill-informed
Tempus
@TempusAI
Jul 16, 2025
We are excited to share that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our Tempus ECG-Low EF software, which uses AI to identify patients who may have a low left ventricular ejection fraction (LVEF). This is our second FDA approved
Tempus
@TempusAI
May 6, 2025
Today, we shared our Q1 2025 results, highlights include: - Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 - Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both
Tempus
@TempusAI
Sep 11, 2025
We are thrilled to announce that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s
Tempus
@TempusAI
Aug 22, 2025
We’re excited to announce our acquisition of @paige_ai, an AI company specializing in digital pathology. This acquisition allows us to grow our dataset, expand our experienced technical team, and establish a strong footprint in digital pathology with an industry leading
Tempus
@TempusAI
Jan 21, 2025
We’re excited to announce the national launch of olivia, our AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. The app enables patients
Tempus
@TempusAI
Sep 22, 2025
We’re excited to share that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. The Tempus xR IVD assay is a qualitative next
Tempus
@TempusAI
Apr 23, 2025
Today, we announced that we're building the largest foundation model that's ever been built in oncology, in collaboration with @AstraZeneca and @pathos. This project is the culmination of years of work. A foundation model like this has the potential to unlock a myriad of
tempus.com
News
For all media inquiries, please contact [email protected]
Tempus
@TempusAI
Sep 4, 2025
We’re excited to share an expansion of our longstanding collaboration with @NorthwesternMed to fully integrate David, our #gen-AI clinical co-pilot, within Northwestern’s #EHR platform for its clinical care team. This integration marks a new chapter in the our shared commitment
Tempus
@TempusAI
Aug 26, 2025
Today, Tempus marks a decade of advancing data-driven precision medicine. We started with a mission to bring the power of artificial intelligence to healthcare, and today, we continue to build solutions that help physicians and researchers improve patient outcomes. Thank you to
00:00
Tempus
@TempusAI
Feb 24, 2025
Today we shared our fourth quarter and full year 2024 results, including: - Revenue growth accelerated to 35.8% year-over-year in the fourth quarter of 2024 - Gross profit growth accelerated to 49.7% in the fourth quarter of 2024, led by Data and Services - Ended the year with
Tempus
@TempusAI
Jun 1, 2025
We're excited to share the expansion of Tempus One—our generative AI clinical assistant—with direct integration into EHR systems. The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to maximize workflow. Learn more
Tempus
@TempusAI
Jan 31, 2025
A leading global pharmaceutical company leveraged Tempus Next to identify patients who may not be receiving guideline-based HER2 testing and gather insights on how to close that care gap. The Tempus Next HER2 program was able to identify 550 patients as potentially HER2+ and
Tempus
@TempusAI
Sep 19, 2025
We're honored to be included, alongside @paige_ai, in @TIME's inaugural list of the World's Top HealthTech Companies of 2025. Our team is as dedicated as ever to building innovative tech solutions oriented around clinical care and research products—and the virtuous cycle between
World's Top HealthTech Companies of 2025
From time.com